Economy/Home · Economy

Peptron Plunges 6.28%... Will It Hold the 90,000-Won Level on November 2? Alteogen, ABL Bio and Other Biotech Stocks Decline Together

As Peptron fell more than 6%, approaching the 90,000-won level, attention is focused on whether investment sentiment across the biotech sector will recover on Monday, November 2. ## Peptron Falls 6.28%... Gap to 90,000-Won Level Narrows to 1,100 Won In the latest trading session, Peptron closed at

Wooil Shim
Staff Reporter
13 min read
Peptron Plunges 6.28%... Will It Hold the 90,000-Won Level on November 2? Alteogen, ABL Bio and Other Biotech Stocks Decline Together
CBC News

As Peptron fell more than 6%, approaching the 90,000-won level, attention is focused on whether investment sentiment across the biotech sector will recover on Monday, November 2.

Peptron Falls 6.28%... Gap to 90,000-Won Level Narrows to 1,100 Won In the latest trading session, Peptron closed at 91,100 won, down 6,100 won from the previous session's base price of 97,200 won, a decline of 6.28%. Trading volume was 153,963 shares, with a traded value of 14.3 billion won and a market capitalization of 2.1242 trillion won.

With a drop of more than 6,000 won in a single day, the gap to the 90,000-won level narrowed to 1,100 won. From the current price, a fall to 90,000 won would be only about 1.21%. In Monday's trading, the key focus will be whether buying interest flows in around the 90,000-won level or additional selling pressure emerges. However, 90,000 won is merely an observation benchmark set because it is close to the current price; a separate chart review is needed to determine whether it has repeatedly acted as support in past trading.

Alteogen, ABL Bio, D&D Pharmatech Fall Together Peptron's weakness came amid a broader decline in the biotech sector.

  • Alteogen: Closed at 209,000 won, down 11,000 won (5.00%). Trading volume was 331,500 shares, traded value 71.042 billion won, market capitalization 14.5579 trillion won. The company develops biopharmaceutical-related technologies, and market interest in its technology transfers and R&D results is high, but in this session it could not escape the sector's downward trend.
  • D&D Pharmatech: Closed at 39,900 won, down 1,800 won (4.32%). Trading volume was 486,154 shares, traded value 19.671 billion won, market capitalization 1.8352 trillion won. The company participates in new drug development for metabolic diseases.
  • ABL Bio: Closed at 38,800 won, down 2,200 won (5.37%). Trading volume was 275,526 shares, traded value 10.763 billion won. The company primarily pursues new drug development based on bispecific antibodies.
  • Others: Apexo fell 6.43% (18,350 won), Rznomics fell 7.06% (21,050 won), Ingenia Therapeutics fell 5.74%, and AIMED Bio fell 5.34%.

With major stocks declining simultaneously, there is a greater need to examine the sector-wide price trend alongside individual negatives. However, since each company's R&D schedule, technology transfer contracts, clinical trial progress, and funding conditions differ, it cannot be concluded that the causes of the declines are identical.

Three Key Points for Monday's Session

① Whether the 90,000-won level holds — If selling pressure continues early in the session, watch the movement around 90,000 won. ② Whether a rebound occurs — Any rebound should be measured against whether it exceeds the previous close of 91,100 won. However, a single day's rebound is insufficient to declare the end of the downtrend. ③ Sector-wide movement — Whether selling in Alteogen, ABL Bio, and D&D Pharmatech subsides is a reference indicator for Peptron's investment sentiment. Market interpretation differs depending on whether all stocks rebound simultaneously or only some rise individually. Conversely, if weakness persists, Peptron may not be immune to the sector trend.

Volume changes are also important. Rising volume during a decline indicates active selling, while rising volume during a rebound confirms the persistence of buying interest. However, volume increases alone cannot determine direction.

Comparing Earnings Indicators... Single Figures Are Inconclusive Differences in earnings indicators also appeared among the falling stocks. Alteogen posted revenue of 215.9 billion won with operating profit growth of 320.80%, while ABL Bio posted revenue of 79.3 billion won with operating profit growth of 31.98%. In contrast, Peptron posted revenue of 5.6 billion won with operating profit growth of -28.62%.

However, since the periods covered by these figures are not specified, they cannot be assumed to represent the same accounting period, and operating profit growth rates represent year-over-year changes and should be distinguished from current profitability. In particular, biotech companies' earnings fluctuate significantly depending on when technology transfer contract payments and R&D costs are recognized, making it difficult to evaluate a company's technological capability or growth potential based on a single indicator.

Consider the Characteristics of Biotech Drug Development Companies Unlike conventional manufacturing, the biotechnology sector involves substantial spending during the R&D stage, and companies may lack stable revenue until commercialization. Corporate valuation is influenced more by clinical trial results, technology transfer potential, and commercialization timelines than by revenue or operating profit, and the clinical progress of drug candidates and regulatory approvals are key variables determining long-term outlooks.

Peptron has developed peptide-based drugs and sustained-release drug delivery technology that controls the in-body release of medications. Technology designed to maintain drug efficacy over a set period is a field studied in relation to dosing intervals and medication convenience. However, technological potential and commercial results must be distinguished, and even after technology is secured, additional validation is required through clinical trials, approval, manufacturing, and sales.

It has not been confirmed that this decline was caused by any specific clinical trial result or technology development issue. Rather than attributing it to individual negatives, the overall sector trend should be examined separately from Peptron's own disclosures and business progress. At present, there is insufficient evidence to confirm either a turnaround to the upside or further downside. Ultimately, whether Peptron recovers part of its losses or falls below the 90,000-won level will depend on actual supply and demand and market conditions on Monday.

[This article is a market outlook piece based on the stock price and corporate earnings information provided and does not recommend buying or selling any specific stock. Biotech drug development companies may see increased stock price volatility depending on clinical trials, technology transfers, and regulatory approvals. This article was written with some assistance from AI.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.